1:00 PM ET | 12:00 PM CT | 11:00 AM MT | 10:00 AM PT
This is an unprecedented time for FSHD therapy development. Fulcrum Therapeutics is recruiting for its Phase 3 clinical trial of losmapimod. Dyne Therapeutics and Avidity Biosciences are among several companies that are on the verge of launching Phase 1 and Phase 2 trials. What does this mean or patients? How does one choose a trial and enroll in one? Jeff Statland, MD, co-director of the international FSHD Clinical Trial Research Network (CTRN), will update us on the FSHD drug development landscape. Find out about current and upcoming research studies and clinical trials. Dr. Statland is a professor of neurology at the University of Kansas Medical Center in Kansas City, Kansas.
Please register by clicking on the button to get your personalized link to attend the webinar.